The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen) and Aduhelm (aducanumab). They are used for Duchenne muscular dystrophy and Alzheimer's disease. The FDA's ...
(Bloomberg) -- Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed approval for drugs to fill unmet needs, federal ...
https://www.tipranks.com/news/the-fly/sarepta-could-be-down-on-patient-death-in-fda-database-says-rbc-capital RBC Capital analyst Brian Abrahams says shares of ...
No new safety signals were observed. As part of a collaboration agreement signed in 2019, Sarepta is working with Roche Holdings AG RHHBY. Sarepta is responsible for regulatory approval and ...
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target remains the same with $75.00.
For example, Sarepta has yet to complete its confirmatory ... The decision prompted three members of the panel to quit. Early last year, Biogen pulled the plug on the treatment.
Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target remains the same with $217.00.
(Bloomberg) — Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed approval for drugs to fill unmet needs, federal watchdogs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback